The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Targeting LRRK2 Dysfunction Using Aptamers in People with Parkinson’s Disease
Study Rationale: Activating mutations in LRRK2 are a common cause of Parkinson’s disease (PD). We propose using aptamers to inhibit LRRK2. Aptamers are snippets of DNA or RNA that can fold into shape...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024IND-enabling Studies of a Molecule that Enhances Mitophagy as Disease-modifying Therapy for Parkinson's Disease
Study Rationale: Studies show that Parkinson's disease (PD) is frequently associated with damage to mitochondria, structures that provide cells with the energy they need to function. In particular, a...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024IND-enabling Studies of a Molecule that Enhances Mitophagy as Disease-modifying Therapy for Parkinson's Disease
Study Rationale: Studies show that Parkinson's disease (PD) is frequently associated with damage to mitochondria, structures that provide cells with the energy they need to function. In particular, a...
-
ASAP CRN Competitive Renewal Opportunity, 2024Activation of Transposable Elements as a Trigger of Neuroinflammation in Parkinson’s Disease
Study Rationale: Inflammation is a common event in neurodegenerative diseases such as Parkinson's disease (PD), although its source remains unclear. Many different factors can potentially trigger...
-
ASAP CRN Competitive Renewal Opportunity, 2024Studying the Circuit Dysfunction Underlying Motor and Sleep Deficits in a Progressive Preclinical Model of Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) begins decades before it compromises an individual’s ability to move about in the world and sleep through the night. Understanding how the dysfunction of...
-
ASAP CRN Competitive Renewal Opportunity, 2024Mapping the LRRK2 Signaling Pathway and Uncovering Its Interplay with Other Molecular Components of Parkinson’s Disease
Study Rationale: Genetic mutations that lead to the activation of the enzyme LRRK2 are a major cause of inherited Parkinson's disease (PD). Combining the expertise of our four laboratories, we will...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.